Home › VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
 

Keywords :   


VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers

2013-06-24 09:13:00| drugdiscoveryonline News Articles

VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), recently announced a licensing deal for a novel antibody against an undisclosed hematological cancer target

Tags: deal target candidate licensing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Cheap TVs ahead of Euros help slow price inflation
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Public Advisory Number 14A
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Atlantic Tropical Weather Outlook
02.07Eastern North Pacific Tropical Weather Outlook
02.07Murdoch Netflix rival to launch in UK
02.07Hurricane Beryl Forecast Discussion Number 14
More »